NCT00474812CompletedPhase 2
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
National Cancer Institute (NCI)1 site in 1 country51 target enrollmentStarted: May 2007Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 51
- Locations
- 1
- Primary Endpoint
- Median Overall Survival
Study Overview
Brief Summary
Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.
Detailed Description
PRIMARY OBJECTIVE:
I. Determine the overall survival, including median survival, of patients with metastatic adenocarcinoma of the pancreas treated with dasatinib.
SECONDARY OBJECTIVES:
I. Determine the effects of this drug on quantities of circulating tumor cells in these patients.
II. Determine the time to progression in patients treated with this drug. III. Determine pre- and post-drug fat-free mass and gait speed in patients treated with this drug.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically or cytologically confirmed adenocarcinoma of the pancreas
- •Metastatic disease
- •Measurable or evaluable/nonmeasurable disease
- •No known brain metastases
- •ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
- •Life expectancy > 12 weeks
- •Absolute granulocyte count >= 1,500/mm^3
- •Platelet count >= 100,000/mm^3
- •Hemoglobin > 8.5 g/dL
- •Bilirubin =< 1.5 times upper limit of normal (ULN)
- •AST and ALT =< 2.5 times ULN
- •Creatinine =< 2.0 mg/dL
- •Not pregnant or nursing
- •No history of allergic reactions attributed to compounds of similar chemical or biological composition to dasatinib
- •No QTc prolongation (i.e., QTc interval >= 480 msecs [Fridericia correction]) or other significant ECG abnormalities
- •LVEF normal by MUGA scan
- •No condition that impairs ability to swallow and retain dasatinib tablets, including any of the following:
- •Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
- •Prior surgical procedures affecting absorption
- •Active peptic ulcer disease
- •No clinically significant cardiovascular disease, including any of the following:
- •Myocardial infarction or ventricular tachyarrhythmia within the past 6 months
- •Major conduction abnormality (unless a cardiac pacemaker is present)
- •Recovered from all prior therapy
- •More than 4 weeks since prior adjuvant chemotherapy (6 weeks for nitrosoureas or mitomycin C) and/or radiotherapy
- •No prior chemotherapy for metastatic disease
- •More than 4 weeks since prior EGFR inhibitors (e.g., imatinib mesylate, gefitinib, erlotinib hydrochloride, or lapatinib ditosylate)
- •No prior EGFR inhibitors that target Src kinases
- •At least 7 days since prior and no concurrent agents with proarrhythmic potential
- •No concurrent combination antiretroviral therapy for HIV-positive patients
- •No concurrent grapefruit or grapefruit juice
- •No other concurrent anticancer agents or therapies
- •No concurrent systemic antacids (i.e., H2-receptor antagonists and proton pump inhibitors) [Locally acting antacids (e.g., Maalox, Mylanta) allowed within either 2 hours before or 2 hours after dasatinib therapy]
- •No concurrent uncontrolled illness, including, but not limited to, any of the following:
- •Ongoing or active infection
- •History of significant bleeding disorder, including congenital (von Willebrand's disease) or acquired (anti-factor VIII antibodies) disorders
- •Large pleural effusions
- •Psychiatric illness or social situation that would preclude study compliance
- •More than 7 days since prior and no concurrent CYP3A4 inducers or inhibitors
- •No other concurrent investigational agents
Exclusion Criteria
- Not provided
Arms & Interventions
Dasatinib Treatment
Experimental
Patients receive oral dasatinib twice daily on days 1-28.
Intervention: dasatinib (Drug)
Dasatinib Treatment
Experimental
Patients receive oral dasatinib twice daily on days 1-28.
Intervention: laboratory biomarker analysis (Procedure)
Dasatinib Treatment
Experimental
Patients receive oral dasatinib twice daily on days 1-28.
Intervention: physiologic testing (Procedure)
Outcomes
Primary Outcomes
Median Overall Survival
Time Frame: assessed up to 24 months
From the date of onset of treatment to the date of death and to the date of last follow-up for those still alive, assessed up to 24 months
Secondary Outcomes
- Median Progression Free Survival (PFS)(Up to 5 years)
- Gait Speed(at 8 weeks)
- Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee(Up to 5 years)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
Dasatinib in Treating Patients With Previously Treated Malignant MesotheliomaMalignant MesotheliomaNCT00509041Alliance for Clinical Trials in Oncology46
Terminated
Phase 2
Dasatinib in Treating Patients With Stage IV Pancreatic CancerPancreatic CancerNCT00544908City of Hope Medical Center7
Completed
Phase 2
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryMelanoma (Skin)NCT00700882Eastern Cooperative Oncology Group81
Completed
Phase 2
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT00671788Gynecologic Oncology Group35
Completed
Phase 1
Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeBrain and Central Nervous System TumorsNCT00869401Alliance for Clinical Trials in Oncology217